分析:隔离剂对胆酸腹的有效性和安全性
Saam Dilmaghani1, Joelle BouSaba1, Camille Lupianez-Merly1
1Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Alimentary pharmacology & therapeutics
|October 15, 2025
概括
胆酸分离剂 (BAS) 在患有胆酸性腹的患者中显著改善了便的一致性和频率. 这次元分析发现,BAS对于这种疾病是耐受良好且有效的.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 胆汁酸性腹 (BAD) 是腹占主导地位的刺激性肠综合征的常见原因.
- 它的患病率与腹腔疾病和炎症性肠道疾病相比较.
- 胆酸分离剂 (BAS) 是主要的治疗方法,但它们的有效性需要澄清.
研究的目的:
- 进行系统性审查和元分析,将BAS与安慰剂进行比较,用于治疗BAD.
- 评估BAS对肠道运动一致性和频率的影响.
- 要总结与BAS治疗相关的不良影响.
主要方法:
- 随机对照试验 (RCT) 的系统审查和元分析,将BAS与安慰剂进行比较.
- 从创建开始到2023年8月1日搜索数据库.
- 包括具有BAD客观诊断的研究 (血清/便参数或75SeHCAT).
- 同一主终点:在7天内,便一致性和频率改善≥30%.
主要成果:
- 分析了6个RCT,其中182名参与者在1至8周内评估了BAS.
- 对平行设计试验的元分析显示,使用BAS显著减少了便的一致性 (RR 1.50) 和频率 (RR 2.80).
- 没有显著的异质性 (I2=0%) 和适度的证据确定性.
- 在BAS和安慰剂之间的不良影响中没有统计学上显著的差异.
结论:
- 在客观诊断为BAD的患者中,BAS显示出便一致性和频率的显著和快速改善.
- 胆酸结合剂似乎被很好地容忍.
- 这一元分析为BAS在治疗BAD方面的有效性提供了定量证据.
相关概念视频
Drugs for Treatment of Diarrhea-Predominant IBS
631
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
631
Drugs for Treatment of Constipation-Predominant IBS
717
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
717
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
884
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
884
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
569
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Adsorbents...
569
Drugs for Treatment of Ulcerative Colitis in IBD
456
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
456
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
423
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
423


